This review focuses on osteoporosis, a major skeletal disorder driven by excessive bone resorption, and examines the physiological effects, clinical outcomes, and reasons for discontinuation of Cathepsin K inhibitors developed to date. This evidence concerns the gene CTSK and osteoporosis.